Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment

Journal of Psychopharmacology

Volumn 26, Issue 3, 2012, Pages 380-389

  Cho, Soo Churl ^a   Kim, Bung Nyun ^a   Cummins, Tarrant D R ^b   Kim, Jae Won ^a   Bellgrove, Mark A ^b  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

ADHD; ADRA2A; blood pressure; heart rate; methylphenidate; Mspl; SLC6A2 3081(A T)

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; METHYLPHENIDATE; NORADRENALIN TRANSPORTER;

ADRA2A GENE; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RESPONSE; CHILD; CLINICAL FEATURE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; DRA1 GENE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; ELECTROCARDIOGRAM; ETHNIC GROUP; FEMALE; GENE PRODUCT; GENETIC ASSOCIATION; GENOTYPE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MSP1 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SLC6A2 GENE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHILD; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE UPTAKE INHIBITORS; DRUG MONITORING; ELECTROCARDIOGRAPHY; FEMALE; GENETIC ASSOCIATION STUDIES; HEART RATE; HUMANS; KOREA; MALE; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 84863245674     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111405356     Document Type: Article

References (62)

1. Abikoff HB, Vitiello B, Riddle MA, et al. Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007 ; 17: 581-592 (Pubitemid 350058982)
2. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009 ; 29: 239-247
3. Akaike . A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974 ; 19 (6). 71-723
4. Andrews GD, Lavin A. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology. 2006 ; 31: 594-601 (Pubitemid 43276975)
5. Anon . A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999 ; 56: 1073-1086
6. Anon . National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004 ; 113: 754-761
7. Association AP Diagnostic and Statistical Manual of Mental Disorders. 2000 ) Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC: American Psychiatric Association text revision. Washington, DC: American Psychiatric Association text revision ; 2000 :
8. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006 ; 60: 1111-1120 (Pubitemid 44647216)
9. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002 ; 106: 2459-2465 (Pubitemid 35278802)
10. Bono M, Cases A, Oriola J, et al. Polymorphisms of the human alpha 2A-adrenergic receptor gene in a Catalan population: description of a new polymorphism in the promoter region. Gene Geogr. 1996 ; 10: 151-159 (Pubitemid 27085196)
11. Carson RP, Diedrich A, Robertson D. Autonomic control after blockade of the norepinephrine transporter: a model of orthostatic intolerance. J Appl Physiol. 2002 ; 93: 2192-2198 (Pubitemid 35379347)
12. Cheon KA, Cho DY, Koo MS, et al. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2009 ; 65: 564-570
13. Cho SC, Kim JW, Kim BN, et al. Possible association of the alpha-2A-adrenergic receptor gene with response time variability in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 ; 147B: 957-963
14. da Silva TL, Pianca TG, Roman T, et al. Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. JNeural Transm. 2008 ; 115: 341-345
15. Davies S, Lowry CA, Nutt DJ. Panic and hypertension: brothers in arms through 5-HT?. J Psychopharmacology. 2007 ; 21: 563-566 (Pubitemid 47472728)
16. DuPaul GJ. Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. J Clin Child Psychol. 1991 ; 20: 245-253
17. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry. 2001 ; 40: 525-529 (Pubitemid 32374269)
18. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs. 2010 ; 24: 99-117
19. Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009 ; 19: 329-339
20. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009 ; 166: 992-1001
21. Gruber R, Joober R, Grizenko N, et al. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed withattention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 ; 19: 233-239
22. Gutgesell H, Atkins D, Barst R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry. 1999 ; 38: 1047-1050
23. Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr. 2009 ; 155: 84 89 e81-89
24. Karahalil B, Coskun E, Emerce E. ADRA2A polymorphism and smoking in a Turkish population. Toxicol Ind Health. 2008 ; 24: 171-176
25. Kaufman JBB, Brent D, Rao U, Flynn C, Moreci P. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Life Time Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997 ; 36: 980-988 (Pubitemid 27272932)
26. Kebir O, Tabbane K, Sengupta S, et al. Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. J Psychiatry Neurosci. 2009 ; 34: 88-101
27. Keller NR, Diedrich A, Appalsamy M, et al. Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation. 2004 ; 110: 1191-1196 (Pubitemid 39202331)
28. Kim CHHM, Joung Y, Anderson SL, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci USA. 2006 ; 103: 19164-19169 (Pubitemid 350002844)
29. Kim YSCK, Kim BN, Chang SA, Yoo HJ, Kim JW. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version-Korean Version (K-SADS-PL-K). Yonsei Med J. 2004 ; 45: 81-89 (Pubitemid 38372291)
30. Kobel M, Bechtel N, Weber P, et al. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol. 2009 ; 13: 516-523
31. Kurnik D, Muszkat M, Li C, et al. Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther. 2006 ; 79: 173-185
32. Lario S, Calls J, Cases A, et al. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet. 1997 ; 51: 129-130 (Pubitemid 27149724)
33. Leddy JJ, Waxmonsky JG, Salis RJ, et al. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/ hyperactivity disorder youths. J Child Adolesc Psychopharmacol. 2009 ; 19: 127-136
34. Mayer AF, Schroeder C, Heusser K, et al. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 ; 48: 120-126 (Pubitemid 44297533)
35. McCaffery JM, Pogue-Geile MF, Ferrell RE, et al. Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens. 2002 ; 20: 1105-1114 (Pubitemid 34913628)
36. McGough J, McCracken J, Swanson J, et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 1314-1322 (Pubitemid 44665448)
37. Manual of the ECDEU Assessment Battery. 1970 ) CGI, Clinical Global Impressions. In: GuyWBR (ed) Manual of the ECDEU Assessment Battery, revised edition. Maryland: NIMH. Guy WBR, ed. Maryland: NIMH ; 1970 :
38. Negrao BL, Crafford D, Viljoen M. The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/ hyperactivity disorder. Cardiovasc J Afr. 2009 ; 20: 296-299
39. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 ; 46: 894-921
40. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007 ; 64: 218-224 (Pubitemid 46220779)
41. Ramos-Quiroga JA, Corominas M, Castells X, et al. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2009 ; 9: 1121-1131
42. Rosmond R, Bouchard C, Bjorntorp P. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med. 2002 ; 251: 252-257 (Pubitemid 34227190)
43. Rubia K, Halari R, Christakou A, et al. Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc Lond B Biol Sci. 2009a ; 364: 1919-1931
44. Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology. 2009b ; 57: 640-652
45. Safer DJ. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1992 ; 2: 279-290
46. Schroeder C, Adams F, Boschmann M, et al. Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol. 2004 ; 286: R851-856
47. Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000 ; 342: 541-549 (Pubitemid 30117894)
48. Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007 ; 50: 47-53 (Pubitemid 46986009)
49. So YKNJ, Kim YS, Ko SG, Koh SJ. The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc. 2002 ; 41: 283-289
50. Sober S, Org E, Kepp K, et al. Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLoS One. 2009 ; 4: e6034
51. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998 ; 94: 127-152 (Pubitemid 28352470)
52. Strempel S, Schroeder C, Hemmersbach R, et al. Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation. J Appl Physiol. 2008 ; 104: 756-760 (Pubitemid 351468805)
53. Sung YSCS. The standardization of Korean CGI-I and CGI-S in children. Proceedings of Annual Meeting of Korean Neuropsychiatric Association ; 1995 ; 1995..
54. Tank J, Schroeder C, Diedrich A, et al. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation. 2003 ; 107: 2949-2954 (Pubitemid 36736638)
55. Thompson J, Thompson JR. Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. J Emerg Med. 2010 ; 38: 18-21
56. Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl). 2003 ; 166: 264-270 (Pubitemid 36384773)
57. Wakamatsu A, Nomura S, Tate Y, et al. Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods. 2009 ; 59: 128-134
58. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007 ; 41: 222-230 (Pubitemid 46705737)
59. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005 ; 66: 253-259 (Pubitemid 40314334)
60. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009 ; 124: e75-80
61. Xavier Sole EG, Valls J, Iniesta R, Moreno V SNPstats. Biostatistics and Bioinformatics Unit at Catalan Institute of Oncology ; 2006 :
62. Yang LWY, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 ; 43: 1154-1158 (Pubitemid 39096873)